Hybrid cell line for producing monoclonal antibody to a human monocyte, antigen, antibody and methods

ABSTRACT

Hybrid cell line for production of monoclonal antibody to an antigen found on normal human monocytes and granulocytes. The hybrid is formed by fusing splenocytes from immunized BALB/cJ mice with P3X63Ag8Ul myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.

This application is a continuation of application Ser. No. 432,456,filed Oct. 4, 1982. This is a division of application Ser. No. 110,509,filed Jan. 8, 1980, now U.S. Pat. No. 4,364,936.

FIELD OF THE INVENTION

This invention relates generally to new hybrid cell and morespecifically to hybrid cell lines for production of monoclonal antibodyto an antigen found on normal human monocytes and granulocytes, to theantibody so produced, and to therapeutic and diagnostic methods andcompositions employing this antibody.

DESCRIPTION OF THE PRIOR ART

The fusion of mouse myeloma cells to spleen cells from immunized mice byKohler and Milstein in 1975 [Nature 256, 495-497 (1975)]demonstrated forthe first time that it was possible to obtain a continuous cell linemaking homogeneous (so-called "monoclonal") antibody. Since this seminalwork, much effort has been directed to the production of various hybridcells (called "hybridomas") and to the use of the antibody made by thesehybridomas for various scientific investigations. See, for example,Current Topics in Microbioloqy and Immunology, Volume 81--"LymphocyteHybridomas", F. Melchers, M. Potter, and N. Warner, Editors,Springer-Verlag, 1978, and references contained therein; C. J.Barnstable, et al., Cell, 14, 9-20 (May, 1978); P. Parham and W. F.Bodmer, Nature 276, 397-399 (November, 1978); Handbook of ExperimentalImmunology, Third Edition, Volume 2, D. M. Wier, Editor, Blackwell 1978Chapter 25; and Chemical and Engineering News, Jan. 1, 1979, 15-17.These references simultaneously indicate the rewards and complicationsof attempting to produce monoclonal antibody from hybridomas. While thegeneral technique is well understood conceptually, there are manydifficulties met and variations required for each specific case. Infact, there is no assurance, prior to attempting to prepare a givenhybridoma, that the desired hybridoma will be obtained, that it willproduce antibody if obtained, or that the antibody so produced will havethe desired specificity. The degree of success is influenced principallyby the type of antigen employed and the selection technique used forisolating the desired hybridoma.

The attempted production of monoclonal antibody to human lymphocytecell-surface antigens has been reported only in a few instances. See,for example, Current Topics in Microbiology and Immunology, ibid, 66-69and 164-169. The antigens used in these reported experiments werecultured human lymphoblastoid leukemia and human chronic lymphocyticleukemia cell lines. Many hybridomas obtained appeared to produceantibody to various antigens on all human cells. None of the hybridomasproduced antibody against a predefined class of human lymphocytes.

More recently, the present applicants and others have authored articlesdisclosing the preparation and testing of hybridomas making antibody tocertain T-cell antigens. See, for example, Reinherz, E. L., et al., J.Immunol. 123, 1312-1317 (1979); Reinherz, E. L., et al., Proc. Natl.Acad. Sci., 76,4061-4065 (1979); and Kung, P. C., et al., Science, 206,347-349 (1979).

Additionally, there has been a recent report of production of ananti-macrophage producing clone. See Springer, et al., Eur. J. Immunol.,9, 301 (1979).

It should be understood that there are two principal classes oflymphocytes involved in the immune system of humans and animals. Thefirst of these (the thymus-derived cell or T cell) is differentiated inthe thymus from haemopoietic stem cells. While within the thymus, thedifferentiating cells are termed "thymocytes." The mature T cells emergefrom the thymus and circulate between the tissues, lymphatics, and thebloodstream. These T cells form a large proportion of the pool ofrecirculating small lymphocytes. They have immunological specificity andare directly involved in cell-mediated immune responses (such as graftrejection) as effector cells. Although T cells do not secrete humoralantibodies, they are sometimes required for the secretion of theseantibodies by the second class of lymphocytes discussed below. Sometypes of T cells play a regulating function in other aspects of theimmune system. The mechanism of this process of cell cooperation is notyet completely understood.

The second class of lymphocytes (the bone marrow-derived cells or Bcells) are those which secrete antibody. They also develop fromhaemopoietic stem cells, but their differentiation is not determined bythe thymus. In birds, they are differentiated in an organ analogous tothe thymus, called the Bursa of Fabricius. In mammals, however, noequivalent organ has been discovered, and it is thought that these Bcells differentiate within the bone marrow.

It is now recognized that T cells are divided into at least severalsubtypes, termed "helper", "suppressor", and "killer" T cells, whichhave the function of (respectively promoting a reaction, suppressing areaction, or killing (lysing) foreign cells. These subclasses are wellunderstood for murine systems, but they have only recently beendescribed for human systems. See, for example, R. L. Evans, et al.,Journal of Experimental Medicine, Volume 145, 221-232, 1977; and L.Chess and S. F. Schlossman--"Functional Analysis of Distinct HumanT-Cell Subsets Bearing Unique Differentiation Antigens", in"Contemporary Topics in Immunobiology", O. Stutman, Editor, PlenumPress, 1977, Volume 7, 363-379.

The ability to identify or suppress classes or subclasses of T cells isimportant for diagnosis or treatment of various immunoregulatorydisorders or conditions.

For example, certain leukemias and lymphomas have differing prognosisdepending on whether they are of B cell or T cell origin. Thus,evaluation of the disease prognosis depends upon distinguishing betweenthese two classes of lymphocytes. See, for example, A. C. Aisenberg andJ. C. Long, The American Journal of Medicine, 58:300 (March, 1975); D.Belpomme, et al., in "Immunological Diagnosis of Leukemias andLymphomas", S. Thierfelder, et al., eds, Springer, Heidelberg, 1977,33-45; and D. Belpomme, et al., British Journal of Haematology, 1978,38, 85.

Certain disease states (e.g., juvenile rheumatoid arthritis,malignancies, and agammaglobulinemia) are associated with an imbalanceof T cell subclasses. It has been suggested that autoimmune diseasesgenerally are associated with an excess of "helper" T cells or adeficiency of certain "suppressor" T cells, while agammaglobulinemia isassociated with an excess of certain "suppressor" T cells or adeficiency of "helper" T cells. Malignancies generally are associatedwith an excess of "suppressor" T cells.

In certain leukemias, excess T cells are produced in an arrested stageof development. Diagnosis may thus depend on the ability to detect thisimbalance or excess and to determine which developmental stage is inexcess. See, for example, J. Kersey, et al., "Surface Markers DefineHuman Lymphoid Malignancies with Differing Prognoses" in Haematoloqy andBlood Transfusion, Volume 20, Springer-Verlag, 1977, 17-24, andreferences contained therein; and E. L. Reinherz, et al., J. Clin.Invest., 64, 392-397 (1979).

Acquired agammaglobulinemia, a disease state in which no immune globulinis produced, comprises at least two distinct types. In type I thefailure to produce immune globulin is due to an excess of suppressor Tcells, while in type II it is due to a lack of helper T cells. In bothtypes, there appears to be no defect or lack in the patients' B cells,the lymphocytes which are responsible for the actual secretion of theantibody; however, these B cells are being either suppressed or "nothelped", resulting in greatly decreased or absent immune globulinproduction. The type of acquired agammaglobulinemia may thus bedetermined by testing for an excess of suppressor T cells or an absenceof helper T cells.

On the therapeutic side, there is some suggestion, as yet not definitelyproven, that administration of antibodies against the subtype of T cellin excess may have therapeutic benefit in autoimmune disease ormalignancies. For example, a helper T cell cancer (certain cutaneous Tcell lymphomas and certain T cell acute lymphoblastic leukemias) may betreated by an antibody to a helper T cell antigen. Treatment ofautoimmune disease caused by an excess of helper cells may also beaccomplished in the same fashion. Treatment of diseases (e.g.,malignancies or type I acquired agammaglobulinemia) due to an excess ofsuppressor T cells may be treated by administration of an antibody to asuppressor T cell antigen.

Antisera against the entire class of human T cells (so-called antihumanthymocyte globulin or ATG) has been reported useful therapeutically inpatients receiving organ transplants. Since the cell-mediated immuneresponse (the mechanism whereby transplants are rejected) depends upon Tcells, administration of antibody to T cells prevents or retards thisrejection process. See, for example, Cosimi, et al., "RandomizedClinical Trial of ATG in Cadaver Renal Allgraft Recipients: Importanceof T Cell Monitoring", Surgery 40:155-163 (1976) and referencescontained therein.

Lymphocytes, however, comprise only one class of leukocyte. The othertwo classes, granulocytes and monocytes, are also important in thefunction of the immune systems of humans and animals. In particular,macrophages, which are a type of monocytes, are extensively involved inimmune function. For example, although macrophages themselves do notsecrete antibody, they have been found necessary for the cooperation ofT cells in the production of antibody by B cells.

Macrophages are also required for the generation of cytotoxic T cellsand for the occurrance of a proliferative response by T cells inreaction to mitogens such as PHA or Con A. Although there has beenspeculation about the function of the macrophage in these processes, itsprecise role is not known. See, for example, E.S. Golub, The CellularBasis of the Immune Response, Sinauer Associates, Sunderland, Mass.,1977, pages 146-158.

The identification and suppression of human T cell and monocyte classesand subclasses has previously been accomplished by the use ofspontaneous autoantibodies or selective antisera for human T cellsobtained by immunizing animals with human T cells, bleeding the animalsobtain serum, and adsorbing the antiserum with (for example) autologousbut not allogeneic B cells to remove antibodies with unwantedreactivities. The preparation of these antisera is extremely difficult,particularly in the adsorption and purification steps. Even the adsorbedand purified antisera contain many impurities in addition to the desiredantibody, for several reasons. First, the serum contains millions ofantibody molecules even before the T cell immunization. Second, theimmunization causes production of antibodies against a variety ofantigens found on all human T cells injected. There is no selectiveproduction of antibody against a single antigen. Third, the titer ofspecific antibody obtained by such methods is usually quite low, (e.g.,inactive at dilutions greater than 1:100) and the ratio of specific tonon-specific antibody is less than 1/10⁶.

See, for example, the Chess and Schlossman article referred to above (atpages 365 and following) and the Chemical and Engineering News articlereferred to above, where the deficiencies of prior art antisera and theadvantages of monoclonal antibody are described.

SUMMARY OF INVENTION

There has now been discovered a novel hybridoma (designated OKM1 ) whichis capable of producing novel monoclonal antibody against an antigenfound on normal human peripheral blood monocytes and granulocytes butnot on normal human peripheral lymphoid cells (T cells, B cells, or nullcells), thymocytes, lymphoblastoid cell lines, or tumor cells of T or Bcell lineage.

The antibody so produced is monospecific for a single determinant onnormal human peripheral blood monocytes and granulocytes and containsessentially no other anti-human immune globulin, in contrast to priorart antisera (which are inherently contaminated with antibody reactiveto numerous human antigens) and to prior art monoclonal antibodies(which are not monospecific for a human monocyte antigen). Moreover,this hybridoma can be cultured to produce antibody without the necessityof immunizing and killing animals, followed by the tedious adsorptionand purification steps necessary to obtain even the impure antisera ofthe prior art.

It is accordingly one object of this invention to provide hybridomaswhich produce antibodies against an antigen found on normal humanperipheral blood monocytes and granulocytes.

It is a further aspect of the present invention to provide methods forpreparing these hybridomas.

A further object of the invention is to provide essentially homogeneousantibody against an antigen found on normal human peripheral bloodmonocytes and granulocytes.

A still further object is to provide methods for treatment or diagnosisof disease or for identification of monocyte subclasses employing thisantibody.

Other objects and advantages of the invention will become apparent fromthe examination of the present disclosure.

In satisfaction of the foregoing objects and advantages, there isprovided by this invention a novel hybridoma producing novel antibody toan antigen found on normal human peripheral blood monocytes andgranulocytes (but not on normal human peripheral lymphoid cells,thymocytes, lymphoblastoid cell lines or tumor cells of T or B celllineage), the antibody itself, and diagnostic and therapeutic methodsemploying the antibody. The hybridoma was prepared generally followingthe method of Milstein and Kohler. Following immunization of mice withnormal E rosette purified human mononuclear cells, the immunized micewere fused with cells from a mouse myeloma line and the resultanthybridomas screened for those with supernatants containing antibodywhich gave selective binding to normal E rosette positive and E rosettenegative human peripheral blood lymphocyte populations. The desiredhybridomas were subsequently cloned and characterized. As a result, ahybridoma was obtained which produces antibody (designated OKM1 )against an antigen on normal human peripheral blood monocytes.

In view of the difficulties indicated in the prior art and the lack ofsuccess reported using malignant cell lines as the antigen, it wassurprising that the present method provided the desired hybridoma. Itshould be emphasized that the unpredictable nature of hybrid cellpreparation does not allow one to extrapolate from one antigen or cellsystem to another. In fact, the present applicants have discovered thatthe use of a T cell malignant cell line or purified antigens separatedfrom the cell surface as the antigen were generally unsuccessful.

Both the subject hybridoma and the antibody produced thereby areidentified herein by the designation "OKM1 ", the particular materialreferred to being apparent from the context. The subject hybridoma wasdeposited on Dec. 13, 1979, at the American Type Culture Collection,12301 Parklawn Drive, Rockville, Md. 20852, and was given the ATCCaccession number CRL 8026.

The preparation and characterization of the hybridoma and the resultantantibody will be better understood by reference to the followingdescription and Examples.

DETAILED DESCRIPTION OF THE INVENTION

The method of preparing the hybridoma generally comprises the followingsteps:

A. Immunizing mice with normal human peripheral blood mononuclear cells.While it has been found that female BALB/cJ mice are preferred, it iscontemplated that other mouse strains could be used. The immunizationschedule and thymocyte concentration should be such as to produce usefulquantities of suitably primed splenocytes. Three immunizations atfourteen day intervals with 2×10⁷ cells/mouse/injection in 0.2 mlphosphate buffered saline has been found to be effective.

B. Removing the spleens from the immunized mice and making a spleensuspension in an appropriate medium. About one ml of medium per spleenis sufficient. These experimental techniques are well-known.

C. Fusing the suspended spleen cells with mouse myeloma cells from asuitable cell line by the use of a suitable fusion promoter. Thepreferred ratio is about 5 spleen cells per myeloma cell. A total volumeof about 0.5-1.0 ml of fusion medium is appropriate for about 10⁸splenocytes. Many mouse myeloma cell lines are known and available,generally from members of the academic community or various depositbanks, such as the Salk Institute Cell Distribution Center, La Jolla,Calif. The cell line used should preferably be of the so-called "drugresistant" type, so that unfused myeloma cells will not survive in aselective medium, while hybrids will survive. The most common class is8-azaguanine resistant cell lines, which lack the enzyme hypoxanthineguanine phophoribosyl transferase and hence will not be supported by HAT(hypoxanthine, aminopterin, and thymidine) medium. It is also generallypreferred that the myeloma cell line used be of the so-called"non-secreting" type, in that it does not itself produce any antibody,although secreting types may be used. In certain cases, however,secreting myeloma lines may be preferred. While the preferred fusionpromoter is polyethylene glycol having an average molecular weight fromabout 1000 to about 4000 (commercially available as PEG 1000, etc.),other fusion promoters known in the art may be employed.

D. Diluting and culturing in separate containers, the mixture of unfusedspleen cells, unfused myeloma cells, and fused cells in a selectivemedium which will not support the unfused myeloma cells for a timesufficient to allow death of the unfused cells (about one week). Thedilution may be a type of limiting one, in which the volume of diluentis statistically calculated to isolate a certain number of cells (e.g.,1-4) in each separate container (e.g., each well of a microtiter plate).The medium is one (e.g., HAT medium) which will not support the drugresistant (e.g., 8-azaguanine resistant) unfused myeloma cell line.Hence, these myeloma cells perish. Since the unfused spleen cells arenon-malignant, they have only a finite number of generations. Thus,after a certain period of time (about one week) these unfused spleencells fail to reproduce. The fused cells, on the other hand, continue toreproduce because they possess the malignant quality of the myelomaparent and the ability to survive in the selective medium of the spleencell parent.

E. Evaluating the supernatant in each container (well) containing ahybridoma for the presence of antibody to E rosette positive purified orE rosette negative human peripheral blood lymphocytes.

F. Selecting (e.g., by limiting dilution) and cloning hybridomasproducing the desired antibody.

Once the desired hybridoma has been selected and cloned, the resultantantibody may be produced in one of two ways. The purest monoclonalantibody is produced by in vitro culturing of the desired hybridoma in asuitable medium for a suitable length of time, followed by recovery ofthe desired antibody from the supernatant. The suitable medium andsuitable length of culturing time are known or are readily determined.This in vitro technique produces essentially monospecific monoclonalantibody, essentially free from other specific antihuman immuneglobulin. There is a small amount of other immune globulin present sincethe medium contains xenogeneic serum (e.g., fetal calf serum). However,this in vitro method may not produce a sufficient quantity orconcentration of antibody for some purposes, since the concentration ofmonoclonal antibody is only about 50 μg/ml.

To produce a much greater concentration of slightly less pure monoclonalantibody, the desired hybridoma may be injected into mice, preferablysyngenic or semi-syngenic mice. The hybridoma will cause formation ofantibody-producing tumors after a suitable incubation time, which willresult in a high concentration of the desired antibody (about 5-20mg/ml) in the bloodstream and peritoneal exudate (ascites) of the hostmouse. Although these host mice also have normal antibodies in theirblood and ascites, the concentration of these normal antibodies is onlyabout 5% of the monoclonal antibody concentration. Moreover, since thesenormal antibodies are not antihuman in their specificity, the monoclonalantibody obtained from the harvested ascites or from the serum isessentially free of any contaminating antihuman immune globulin. Thismonoclonal antibody is high titer (active at dilutions of 1:50,000 orhigher) and high ratio of specific to non-specific immune globulin(about 1/20). Immune globulin produced incorporating the light myelomachains are non-specific, "nonsense" peptides which merely dilute themonoclonal antibody without detracting from its specificity.

EXAMPLE I Production of Monoclonal Antibodies A. Immunization andSomatic Cell Hybridization

Female BALB/cJ mice (Jackson Laboratories; 6-8 weeks old) were immunizedintraperitoneally with 2×10⁷ rosette purified human mononuclear cells in0.2 ml of phosphate buffered saline at 14-day intervals. Four days afterthe third immunization, spleens were removed from the mice, and a singlecell suspension was made by pressing the tissue through a stainlesssteel mesh.

Cell fusion was carried out according to the procedure developed byKohler and Milstein. 1×10⁸ splenocytes were fused in 0.5 ml of a fusionmedium comprising 35% polyethylene glycol (PEG 1000) and 5%dimethylsulfoxide in RPMI 1640 medium (Gibco, Grand Island, N.Y.) with2×10⁷ P3X63Ag8Ul myeloma cells supplied by Dr. M. Scharff, AlbertEinstein College of Medicine, Bronx, N.Y. These myeloma cells secreteIgG₁ light chains.

B. Selection and Growth of Hybridoma

After cell fusion, cells were cultured in HAT medium (hypoxanthine,aminopterin, and thymidine) at 37° C. with 5% CO₂ in a humid atmosphere.Several weeks later, 40 to 100 1 of supernatant from cultures containinghybridomas were added to a pellet of 10⁶ peripheral lymphocytesseparated into E rosette positive (E+) and E rosette negative (E-)populations, which were prepared from blood of healthy human donors asdescribed by Mendes (J. Immunol. 111:860, 1973). Detection of mousehybridoma antibodies binding to these cells was determined by indirectimmunofluorescence. Cells incubated with culture supernatants werestained with a fluorescinated goat-anti-mouse IgG (G/M FITC) (MeloyLaboratories, Springfield, Va.; F/p=2.5) and the fluorescentantibody-coated cells were subsequently analyzed on the CytofluorografFC200/4800A (Ortho Instruments, Westwood, Mass.) as described in ExampleIII. Hybridoma cultures containing antibodies reacting specifically withE⁺ lymphocytes (T cells) and/or E⁻ lymphocytes were selected and clonedtwice by limiting dilution methods in the presence of feeder cells.Subsequently, the clones were transferred intraperitoneally by injecting1×10⁷ cells of a given clone (0.2 ml volume) into BALB/cJ mice primedwith 2,6,10,14-tetramethylpentadecane, sold by Aldrich Chemical Companyunder the name Pristine. The malignant ascites from these mice were thenused to characterize mononuclear cells as described below in Example II.The monoclonal antibody produced by one of these clones, which reactedwith a fraction of both E⁺ and E⁻ cells, was termed OKM1 . The subjecthybrid antibody OKM1 was demonstrated by standard techniques to be ofIgG_(2a) subclass.

EXAMPLE II Characterization of OKM1 Reactivity A. Isolation ofMononuclear Cell Populations

Human peripheral blood mononuclear cells were isolated from healthyvolunteer donors (ages 15-40) by Ficoll-Hypaque density gradientcentrifugation (Pharmacia Fine Chemicals, Piscataway, N.J.) followingthe technique of Boyum, Scand. J. Clin. Lab. Invest. 21 (Suppl. 97): 77,1968.

Adherent cells were obtained by a one hour incubation of mononuclearcells in polystyrene dishes (100×20 mm tissue culture dishes) (Falcon,Oxnard, Calif.) in RPMI 1640 (Grand Island Biological Company, GrandIsland, N.Y.) supplemented with 20% pooled human AB serum. After removalof the non-adherent fraction, adherent cells were detached by incubationat 4° C. in serum-free MEM, 2.5 mM EDTA, followed by gentle scrapingwith the rubber tip of a disposable syringe plunger.

Mononuclear cells were separated into E⁺ and E⁻ populations by rosettingwith sheep erythrocytes and differential centrifugation overFicoll-Hypaque. Rosetting was accomplished by centrifugation of themononuclear cells/ sheep erythrocyte mixture for five minutes at 800 rpmand incubating for one hour at 4° C. The erythrocyte: lymphocyte ratiowas 40:1. The E⁺ cells were recovered by lysis of the sheep erythrocyteswith a 0.85% ammonium chloride solution.

Null cells were prepared by similar rosetting on the surfaceimmunoglobulin negative (sIg⁻) population obtained by Sephadex G- 200anti-hum (F(ab¹)₂ chromatography as previously described by Chess, etal., J. Immunol., 113:1113 (1974). Polymorphonuclear leukocytes wereobtained by lysis of the erythrocytes present in the pellet formedduring Ficoll Hypaque centrifugation of peripheral blood.

B. Isolation of Thymocytes

Normal human thymus gland was obtained from patients aged two months to14 years undergoing corrective cardiac surgery. Freshly obtainedportions of the thymus gland were immediately placed in 5% fetal calfserum in medium 199 (Gibco), finely minced with forceps and scissors,and subsequently made into single cell suspensions by being pressedthrough wire mesh. The cells were next layered over Ficoll-Hypaque andspun and washed as previously described in section A above. Thethymocytes so obtained were >95% viable and >90% E rosette positive.

C. Cell Lines of T Lineage and T Acute Lymphoblastic Leukemia Cells

T cell lines CEM and HSB-2, and B cell lines Laz 156 and Laz 388 wereprovided by Dr. H. Lazarus (Sidney Farber Cancer Institute, Boston,Mass.). Leukemic cells were obtained from patients with the diagnosis ofacute myelomonocytic leukemia (AMML; 5 patients) and acute myeloblasticleukemia (AML; 8 patients). Tumor populations were cryopreserved at-196° C. vapor phase liquid nitrogen with 10% DMSO and 20% AB humanserum until the time of surface characterization.

EXAMPLE III Cytofluorographic Analysis and Cell Separation

Cytofluorographic analysis of monoclonal antibodies with all cellpopulations was performed by indirect immuno-fluorescence withfluorescence-conjugated goat anti-mouse IgG (G/M FITC) (MeloyLaboratories) utilizing a Fluorescense Activated Cell Sorter (FACS-I)(Becton, Dickinson, Mountain View, Calif.) or a CytofluorografFC200/4800A (Ortho Instruments). In brief, 1×10⁶ cells were treated with0.15 ml OKM1 at a 1:500 dilution, incubated at 4° C. for 30 minutes, andwashed twice. The cells were then reacted with 0.15 ml of a 1:40dilution G/M FITC at 4° C. for 30 minutes, centrifuged, and washedtwice. Cells were then analyzed on the FACS-I and the intensity offluorescence per cell was recorded on a pulse height analyzer.Background staining was obtained by substituting a 0.15 ml aliquot of1:500 ascites from a BALB/cJ mouse intraperitoneally injected with anon-producing hybrid clone.

In experiments involving antibody and complement mediated lympholysis,thymocytes and peripheral T cells were cultured overnight followingselective lysis and then subsequently analyzed on the Cytofluorograf orFACS.

A. Cytotoxicity Studies

Sensitization cultures for cell-mediated lympholysis (CML) wereestablished by the following procedure. Five X 10⁶ target cells weretreated with 0.2 ml 51_(Cr) sodium chromate (292 μCi/mI) (New EnglandNuclear, Boston, Mass.) and incubated for 90 minutes at 37° C. After twowashes, the cells were diluted to 2×10⁵ /ml in media containing 10% FCS.Twenty 1 of labeled cells were distributed in conical microplate wellswith 20 μl of serial dilutions of hybridoma antibody. Following a onehour incubation at 4° C., 20 μl fresh rabbit serum (1:10) dilution) wereadded to the wells as a source of complement. The plates were incubatedat 37° C. for one hour. One hundred forty μl of media were then added tothe wells and the plates were spun at 400 g for 10 minutes. One hundredμl of supernatant were removed from each well and counted on a gammascintillation counter (Parkard Instrumentation Company, Downer's Grove,Ill.). Specific ⁵¹ Cr release was calculated using the followingformula: ##EQU1## where Exp=mean of the observed triplicate,SR=spontaneous release from the cells incubated with complement alone,and MR=maximum release obtained by treating the cells with the detergentTriton X (1% solution)

Lysis of larger number of cells for subsequent proliferative assays wasdone by resuspending 20 to 50 X 10⁶ mononuclear cells in 1 ml of OKM1 ata 1:250 dilution and incubating at 4° C. for one hour.

Subsequently, 0.1 ml fresh rabbit serum was added and the cells furtherincubated at 37° C. for one hour. After three washes, the cells werecounted and their viability was assessed by Trypan blue exclusion.

B. Proliferative Response Assay

The proliferative response to soluble antigens was measured aspreviously described. Cells were brought up at a concentration of 2×10⁶viable cells/ml in RPMI 1640 supplemented with 20% human AB serum andcultured in microtiter plates in the presence of tetanus toxoid (TT)(Massachusetts Department of Public Health Biological Laboratories,Boston, Mass.), purified protein derivative (PPD) (National Institutesof Health, Bethesda, Md.), or mumps CF antigen (MicrobiologicalAssociates, Walkersville, Md.). The cultures were pulsed after five dayswith 0.2 Ci of [H-methyl] thymidine (³ H TdR) (1.9 μCi/mM specificactivity) (Schwarz-Mann, Orangeburg, N.Y.) and harvested 18 hours lateron a MASH 11 apparatus (Microbiological Associates). ³ H-TdRincorporation was measured in a Packard Liquid Scintillation Counter(Packard Instrumentation Company). Each experimental group was assayedin triplicate and the results are expressed as mean counts per minute(cpm)±the standard error of the mean.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the fluorescence pattern obtained on the FACS afterreacting unfractionated, nonadherent, and adherent normal humanperipheral blood mononuclear cells from donor #1 with OKM1 at a 1:500dilution and G/M FITC. Background fluorescence staining was obtained byincubating each population with a 1:500 dilution of ascitic fluid from amouse injected with a non-producing clone.

FIG. 2 shows the fluorescence obtained on the FACS after reacting normalhuman E⁺ and E⁻ peripheral blood mononuclear cells with OKM1 and G/MFITC.

FIG. 3 shows the fluorescence pattern obtained on the FACS afterreacting normal human Ig⁻, E⁻, nonadherent null cells with OKM1 and G/MFITC.

FIG. 4 shows the lytic capacity of OKM1 and complement on humanmononuclear cells.

The production of the hybridoma and the production and characterizationof the resulting monoclonal antibody were conducted as described in theabove Examples. Although large quantities of the subject antibody wereprepared by injecting the subject hybridoma intraperitoneally into miceand harvesting the malignant ascites, it is clearly contemplated thatthe hybridoma could be cultured in vitro by techniques well-known in theart and the antibody removed from the supernatant.

Peripheral blood mononuclear cells of nine normal donors were separatedinto adherent and nonadherent populations on polystyrene dishes, andeach fraction was analyzed by indirect immunofluorescence on the FACS.The percentages of cells specifically labeled by OKM1 are given in TableI. The mean of positive cells was 27% for unfractionated cells, 18% fornonadherent cells, and 78% for adherent cells. The FACS fluorescenceprofiles of the three pupulations for donor #1 are illustrated inFIG. 1. As seen in FIG. 1A, the fluorescence pattern of OKM1 onunfractionated mononuclear cells is bimodal. A two dimensional mappingof the same population showed that the cells brightly stained by OKM1are also larger. A population of smaller cells with a weakerfluorescence intensity was also detected. Most of these smaller cellsare found in the nonadherent fraction (FIG. 1B). Adherent cells, incontrast, contain the brightly stained larger pupulation (FIG. 1C). Thisreactivity of OKM1 with adherent populations suggested that themononuclear cell recognized by the antibody was a monocyte and providesone test by which the subject antibody may be detected and distinguishedfrom the antibodies.

The study of lymphoid and myeloid cells of different origins gavefurther evidence for this specificity. OKM1 was unreactive with B celllines (Laz 156, and Laz 388), T cell lines (CEM and HSB 2), and threehuman thymocyte preparations. Moreover, three T-CLL, six B-CLL, threeT-ALL, and six non T-ALL tumor cells were also negative. In contrast,OKM1 reacted strongly with 44 to 82% of the cells of five acutemyelomonocytic leukemia (AMML) samples and with about 35% of the cellsin two out of eight acute myeloblastic leukemia (AML) cases. Two myeloidlines, K562 (Lozzio, et al., Blood 45, 321 (1975) and HL 60 (Collins, etal., Native, 270 347 (1977) were negative. Isolated polymorphonuclearleukocytes from four normal donors were brightly labeled. These resultswere consistent with the notion of granulocytes and monocytes beingclosely related cells of common origin. In addition, the data obtainedwith AML cells seemed to indicate that OKM1 reacted preferentially withmonocytic cells with the myeloid lineage. This pattern of reactivityprovides an additional test by which the subject antibody may bedetected and distinguished from other antibodies.

The staining pattern observed on unfractionated, adherent, andnonadherent mononuclear cells suggested that the monocyte populationdefined by the antibody was heterogeneous with respect to size andadherent properties. As surface Ia antigens have been described onsubpopulations of monocytes, the above cell fractions (donor #1) weretested with a monoclonal anti-Ia antibody, OKI1, in order tocharacterize further the phenotype of the cells identified by OKM1 . Thepercentage of OKI1⁺ cells in the nonadherent and adherent fractions were9% and 80% respectively. As Ia bearing B lymphocytes account for some ofthe staining found with OKIl in nonadherent populations, it appearedthat the small, nonadherent cell recognized by OKM1 is mainly Ia⁻. Incontrast, the large, adherent OKM1 ⁺ monocytes carry surface Iadeterminants.

The distribution of OKM1 cells within E⁺ and E⁻ populations is shown inTable II. Although most of the labeled cells were found in the E⁻population, up to 22% (mean, 13%) positive cells were present in the E⁺fraction. FACS fluorescence profiles for E⁻ and E⁺ cells are shown inFIG. 2. E⁻ cells had a bimodal staining pattern due to the presence ofthe large and small cells described above. The fluorescence intensity onthe E⁺ population was more homogeneous. The positive cells found in thisfraction were of a small size and largely Ia⁻ (mean reactivity withOKIl, 3%). This pattern of reactivity is a further test by which thesubject antibody may be detected and distinguished from otherantibodies.

A representative FACS histogram of OKM1 reactivity with the Ig⁻, E⁻,nonadherent cell population is illustrated in FIG. 3. Eighty-fourpercent of the cells were stained with OKM1 and 11% with OKI 1. studiesindicated that the OKM1 ⁺, Ia⁻ nonadherent cell accounted surprisinglyfor most of the Null cell population. This pattern of reactivity is astill further test by which the subject antibody may be detected anddistinguished from other antibodies.

Complement mediated lysis assays were performed on several of thepopulations described above. Serial dilutions of OKM1 were tested onunfractionated, nonadherent, and adherent cells. Specific ⁵¹ Cr releasevalues are shown in FIG. 4. There was a good correlation between thepercentages found by indirect immunofluorescence (donor #5, Table I) andcomplement mediated lysis for each population.

E⁺ and E⁻ cells were also studied and the data obtained are presented inTable III. Again, the specific ⁵¹ Cr release results corresponded to thelabeling found by indirect immunofluorescence (donors #8, #9, and #10).

The effect of OKM1 and complement pretreatment on a known monocytedependent T cell function, i.e., proliferation to soluble antigens, wasstudied. Mononuclear cells from a normal donor were incubated with OKM1antibody (1:250 dilution) in the presence of complement. Graded amountof autologous adherent cells were added to this pre-treated populationprior to triggering with soluble antigens. As shown in Table IV, OKM1and complement treated mononuclear cells did not proliferate in responseto soluble antigens, while the addition of 1% adherent cells couldrestore their proliferative response. As incubation with OKM1 antibodiesin the absence of complement did not affect this T cell function, theeffect seen in the presence of complement could be attributed tospecific killing of monocytes within the mononuclear cell population.

It should be noted that, when 10 to 20% adherent cells were added toOKM1 pretreated cells, both the background and the antigen inducedproliferation were increased when compared to the untreated population.

The effect of OKM1 on CML is also a test by which the subject antibodymay be detected and distinguished from other antibodies.

Table V shows the relationship between levels of peripheral T cells andT cell subsets and various disease states. These relationships may beused for diagnostic purposes (e.g., to detect acute infectiousmononucleosis) by analyzing the blood sample of an individual suspectedof having one of these disease states to determine the levels of T cellsand T cell subsets. These relationships may also be used for therapeuticpurposes where the cause of the disease state is an elevated level of aT cell subset (e.g., Type I acquired agammaglobulinemia). Fortherapeutic use, administration of the appropriate monoclonal antibodyto a patient with an elevated T cell subset level will decrease oreliminate the excess. The relationships shown in Table V are a furtherway in which OKT11 antibody may be detected and distinguished from otherantibodies.

Other monoclonal antibody producing hybridomas prepared by the presentapplicants (designated OKT1, OKT3, OKT4, and OKT5) are described andclaimed in the following U.S. patent applications: Ser. No. 22,132,filed Mar. 20, 1979; Ser. No. 33,639, filed Apr. 26, 1979; Ser. No.33,669, filed Apr. 26, 1979; Ser. No. 76,642, filed Sept. 18, 1979; andSer. No. 82,515, filed Oct. 9, 1979. Still other monoclonal antibodyproducing hybridomas prepared by the present applicants (designatedOKT6, OKT8, OKT9, and OKT10) are described and claimed in U.S. patentapplications filed on Dec. 4, 1979 and entitled:

Hybrid Cell Line for Producing Monoclonal Antibody to a Human ThymocyteAntigen, Antibody, and Methods; Hybrid Cell Line For ProducingComplement-Fixing Monoclonal Antibody to Human Suppressor T Cells,Antibody, and Methods; Hybrid Cell Line For Producing MonoclonalAntibody to Human Early Thymocyte Antigen, Antibody, and Methods; andHybrid Cell Line For Producing Monoclonal Antibody to a HumanProthymocyte Antigen, Antibody, and Methods. A further monoclonalantibody producing hybridoma prepared by the present applicants(designated OKT11) is described and claimed in a U.S. patent applicationfiled on even date herewith and entitled: Hybrid Cell Line for ProducingAntibody for a Human T Cell Antigen, Antibody, and Methods.

These applications are incorporated herein by reference.

According to the present invention there are provided a hybridomacapable of producing antibody against an antigen found on normal humanmonocytes, a method for producing this hybridoma, monoclonal antibodyagainst an antigen found on normal human monocytes, methods forproducing the antibody, and methods and compositions for treatment ordiagnosis of disease or identification of monocyte subclasses employingthis antibody.

                  TABLE I                                                         ______________________________________                                        Percentage of Cells Reactive with OKMl by                                     Indirect Immunofluorescence                                                   Percentage of Positive Cells                                                  Donor   F/H.sup.a F/H Non Adherent                                                                            Adherent                                      ______________________________________                                        1       32.3      20.4          80.6                                          2       28.2      23.6          83.4                                          3       20.4      17.5          67.6                                          4       20.6      16.1          74.4                                          5       26.1      16.5          82.7                                          6       28.1      20.2          74.2                                          7       30.5      ND            84.8                                          8       27.7      ND            80.7                                          9       28.7      11.2          76.0                                          Mean    26.9      17.9          78.2                                          ______________________________________                                         .sup.a Mononuclear cells prepared by centrifugation on FicollHypaque          gradient.                                                                

                  TABLE II                                                        ______________________________________                                        Percentage of Cells Reactive with OKM1 in E Rosette                           Positive and E Rosette Negative Populations                                              Percentage of Positive Cells                                       Donor        E.sup.+    E.sup.-                                               ______________________________________                                        1            18.2       64.2                                                  2            12.1       51.2                                                  3            13.8       47.9                                                  4            9.7        67.9                                                  5            14.2       41.5                                                  6            22.2       69.0                                                  7            11.5       51.2                                                  8            10.6       58.6                                                  9            9.4        55.6                                                  10           12.8       68.5                                                  Mean         13.5       57.5                                                  ______________________________________                                    

                  TABLE III                                                       ______________________________________                                        OKM1 Reactivity by Complement Mediated Lysis on                               E Rosette Positive and E Rosette Negative Populations                         Percent Specific .sup.51 Cr Release                                           ______________________________________                                        Antibody E+                                                                   Dilution Donor #8    Donor #9  Donor #10                                      ______________________________________                                        10.sup.-2                                                                              11.2 ± 3 9.8 ± 2                                                                              12.5 ± 1                                    10.sup.-3                                                                              7.8 ± 2  10.7 ± 2                                                                             11.7 ± 2                                    10.sup.-4                                                                              4.4 ± 2  9.0 ± 2                                                                              11.2 ± 2                                    10.sup.-5                                                                              1.5 ± 1  6.7 ± 1                                                                              5.5 ± 2                                            E.sup.-                                                                10.sup.-2                                                                              71.5 ± 4 68.7 ± 5                                                                             74.3 ± 5                                    10.sup.-3                                                                              73.0 ± 3 63.3 ± 7                                                                             70.6 ± 4                                    10.sup.-4                                                                              67.0 ± 5 57.3 ± 4                                                                             70.9 ± 3                                    10.sup.-5                                                                              56.7 ± 3 52.9 ± 3                                                                             60.2 ± 5                                    ______________________________________                                    

                                      TABLE IV                                    __________________________________________________________________________    Effect of Pre treatment of Mononuclear Cells with OKM1 and                    C' on Antigen Induced Proliferative Responses.sup.a                           .sup.3 H--Thymidine Incorporation                                             Cell                                                                          Population                                                                             Media  TT     PPD     Mumps                                          __________________________________________________________________________    F/H      385 ± 88                                                                          1,767 ± 425                                                                       5,063 ± 1,010                                                                      19,094± 3,139                               F/H OKM1 + C'                                                                          144 ± 10                                                                          142 ± 12                                                                          162 ± 23                                                                           254 ± 4                                     F/H OKM1 + C'                                                                 +1% Adherent                                                                           190 ± 51                                                                          1,358 ± 209                                                                       5,777 ± 1,013                                                                      7,269 ± 1,090                               cells                                                                         ±10% Adherent                                                                       1,425 ± 259                                                                       4,128 ± 921                                                                       16,412 ± 2,747                                                                     38,558 ± 1,680                              cells                                                                         ±20% Adherent                                                                       1,944 ± 665                                                                       5,926 ± 1,429                                                                     13,182 ± 3,007                                                                     40,065 ± 5,810                              cells                                                                         Adherent cells                                                                         192 ± 69                                                                          261 ± 186                                                                         224 ± 95                                                                           804 ± 42                                    __________________________________________________________________________     .sup.a All cultures done in triplicate. Results expressed as mean counts      per minute standard error of the mean                                         .sup.b TT (Tetanus Toxoid): 10 g/ml                                           .sup.c PPD (Purified Protein Derivative): 10 g/ml                             .sup.d Mumps: 1/20 dilution                                              

                                      TABLE V                                     __________________________________________________________________________    PERIPHERAL MONONUCLEAR CELL LEVELS IN DISEASE STATES                                      Monoclear Cell Levels                                             Disease State                                                                             OKT3.sup.+                                                                         OKT4.sup.+                                                                          OKT5                                                                              OKT8                                                                              OKT6                                                                              OKT11                                                                             OKM1                                   __________________________________________________________________________    Primary Biliary                                                                           N    +     -   -   -   ++  -                                      Cirrhosis (2)                                                                 Multiple Sclerosis                                                                        -    N     -   -   -   -   +                                      (advanced disease) (8)                                                        Myasthenia Gravis                                                                         O    O     O   O   O   -   +                                      (early untreated) (3)                                                         Acute Graft vs Host (3)                                                                   O to -                                                                             -     O   +   +   +   -                                      Acquired Agamma                                                               globulinemia                                                                  Type I                 +                                                      Type II          O                                                            Hyper IgE (4)                                                                             -    N     O to -                                                                            O to -                                                                            -   +   N                                      Acute Infectious Mono-                                                                    +    O to --                                                                             ++  ++  O   ++  -                                      nucleosis (4)*                                                                Hodgkins Disease                                                              Stages I & II                                                                             N    N     N   N   O   O   N                                      Stages III & IV                                                                           --   N     N   N   O   O   ++                                     Psoriasis (3/5)                                                                           N    + to ++                                                                             N   N   O   N   N                                      __________________________________________________________________________     N = within normal limits                                                      O = absent                                                                    + = above normal                                                              ++ = greatly above normal                                                     - = below normal                                                              -- = greatly below normal                                                     *these levels return to normal about one week prior to the disappearance      of clinical symptoms                                                          The numbers in parentheses indicate the number of patients evaluated.    

Although only a single hybridoma producing a single monoclonal antibodyagainst a human thymocyte antigen is described, it is contemplated thatthe present invention encompasses all monoclonal antibodies exhibitingthe characteristics described herein. It was determined that the subjectantibody OKM1 belongs to the subclass IgG_(2a), which is one of foursubclasses of murine IgG. These subclasses of immune globulin G differfrom one another in the so-called "fixed" regions, although an antibodyto a specific antigen will have a so-called "variable" region which isfunctionally identical regardless of which subclass of immune globulin Git belongs to. That is, a monoclonal antibody exhibiting thecharacteristic described herein may be of subclass IgG₁, IgG₂ a, IgG₂ b,or IgG₃, or of classes IgM, IgA, or other known Ig classes. Thedifferences among these classes or subclasses will not affect theselectivity of the reaction pattern of the antibody, but may affect thefurther reaction of the antibody with other materials, such as (forexample) complement or anti-mouse antibodies. Although the subjectantibody is specifically IgG_(2a), it is contemplated that antibodieshaving the patterns of reactivity illustrated herein are included withinthe subject invention regardless of the immune globulin class orsubclass to which they belong.

Further included within the subject invention are methods for preparingthe monoclonal antibodies described above employing the hybridomatechnique illustrated herein. Although only one example of a hybridomais given herein, it is contemplated that one skilled in the art couldfollow the immunization, fusion, and selection methods provided hereinand obtain other hybridomas capable of producing antibodies having thereactivity characteristics described herein. Since the individualhybridoma produced from a known mouse myeloma cell line and spleen cellsfrom a known species of mouse cannot be further identified except byreference to the antibody produced by the hybridoma, it is contemplatedthat all hybridomas producing antibody having the reactivitycharacteristics described above are included within the subjectinvention, as are methods for making this antibody employing thehybridoma.

Further aspects of the invention are methods of treatment or diagnosisof disease employing the monoclonal antibody OKM1 or any othermonoclonal antibody exhibiting the pattern of reactivity providedherein. The subject antibody may be used to detect and study monocytedifferentiation. Moreover, the subject antibody may be employed todiagnose disease states as shown in Table V. These techniques may beemployed using OKM1 antibody alone or in combination with otherantibodies (e.g., OKT3-OKT11). Patterns of reactivity with a panel ofantibodies to T cells and T cell subsets and/or monocyte subsets willallow more precise detection of certain disease states then is possibleusing prior diagnostic methods. As an example, AMML and (to a lesserextent) AML may be detected by reacting leukemia cells from individualswith OKM1 antibody.

Treatment of disease states (e.g., malignancies such as AMML)manifesting themselves as an excess of OKM1 ⁺ cells may be accomplishedby administration of a therapeutically effective amount of OKM1 antibodyto an individual in need of such treatment. By selective reaction withOKM1 ⁺ antigen, the effective amount of OKM1 antibody will reduce theexcess of OKM1 ⁺ cells, thus ameliorating the effects of the excess.

Diagnostic and therapeutic compositions comprising effective amounts ofOKM1 antibody in admixture with diagnostically or pharmaceuticallyacceptable carriers, respectively, are also included within the presentinvention.

What is claimed is:
 1. An IgG monoclonal-antibody-producing hybridomaformed by fusion of spleen cells from a mouse previously immunized withhuman mononuclear cells and cells from a mouse myeloma line, whichantibody:(a) reacts with an antigen found on normal human monocytes andgranulocytes, but not with normal human peripheral T cells, B cells,Null cells, thymocytes, lymphoblastoid cell lines, or tumor cells of Tor B cell lineage;
 2. The hybridoma of claim 1 wherein the antibodyproduced thereby is of subclass IgG_(2a).
 3. The hybridoma of claim 1which is formed by fusion of P3X63Ag8Ul myeloma cells and spleen cellsfrom a BALB/cJ mouse previously immunized with human mononuclear cells.4. A hybridoma having the identifying characteristics of ATCC CRL 8026.5. A hybridoma formed by fusion of cells from a mouse myeloma line andspleen cells from a mouse previously immunized with human mononuclearcells with is capable of producing a monoclonal antibody which reactswith an antigen found on normal human monocytes and granulocytes, butnot with normal human peripheral T cells or B cells.
 6. A method fordetection of a deficiency or excess of OKM1 ⁺ cells in an individualwhich comprises reacting a monocyte-containing composition from saidindividual with a diagnostically-effective amount of the antibodyproduced by the hybridoma of claim 5 and measuring the percentage of themonocyte population which reacts with said antibody.
 7. The method ofclaim 6 wherein the excess is AMML.